We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Nov 22, 2019

International Diabetes Federation Congress 2019

Usage of anti-hyperglycemic agents in type 2 diabetic patients with hemodialysis at two hemodialysis centers in Cambodia

Type 2 diabetes

Hemodialysis

Anti-hyperglycemic agents

Management

Cambodia

Abstract

7

Views

7

Views

Abstract

Fullscreen

thumbnail

Keywords

Type 2 diabetes

Hemodialysis

Anti-hyperglycemic agents

Management

Cambodia

Abstract

Introduction: The hyperglycemia in type 2 diabetic patients with hemodialysis is different from type 2 diabetic patients without hemodialysis. We need to change the oral medication, adjust the dose or switch to insulin. Until presence, there are no data about the use of antihyperglycemic agents among type 2 diabetic patients with hemodialysis in Cambodian population. Objectives: The purpose of this study is to explore the usage of antihyperglycemic agents (AHA) among type 2 diabetic patients with hemodialysis at Calmette hospital and Preah Ket Mealea hospital, Phnom Penh, Cambodia. Materials and Methods: This is a cross-sectional study conducted at Calmette hospital and Preah Ket Mealea hospital among type 2 diabetic patients undergoing hemodialysis from September 3rd, 2018 to September 30th, 2018. Out of 347 patients who receiving hemodialysis, only 101 patients were met inclusion criteria. 101 patients conveniently selected. The data of the patients were collected by checklist and entered into Excel sheet, and then exported to STATA Version 13.1 for analysis. Results: Among 101 cases, female patients represented 43 (42.6 %) and male patients represented 58 (57.4 %). The average age in the study was 62 years old. Almost 100 % the patients in our study had multi-complications (macro- and micro-vascular complications) related to diabetes. Moreover, we noted as well that the patients had comorbidities such as hypertension 100 cases (99.01 %) and dyslipidemia 66 cases (65.4 %). We found that 61 cases (60.4 %) stopped the AHA when they started hemodialysis. And, 40 cases (39.6 %) still continued AHA, 27 cases (67.5 %) were treated with insulin. The insulin therapy formulas were premixed (2 injections), basal-bolus and rapid-acting insulin as needed. Besides that, oral antidiabetic drugs were prescribed in 13 cases (32.5 %). Repaglinide was the only oral medication being prescribed. Conclusions: In our study, we observed that many patients did not need any more antihyperglycemic agents when they started hemodialysis. Repaglinide was the most prescribed oral antihyperglycemic agent. And, two times premixed insulin seemed to be more preferable than basal-bolus.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.